Intraoperative Calcar Fractures in Uncemented Total Hip Replacement: A Systematic Review.

JBJS RevSep 23, 2026 (epub)
Clinical ResearchOrthopedic Surgery

Amaar Awais Ali, Muhammad Yasir Tarar, Zubayr Ali et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review analyzed 60 studies involving 465,030 primary uncemented total hip arthroplasties (THAs) to evaluate intraoperative calcar fractures (IOCFs). The overall incidence of IOCFs was 0.74%, with stem impaction being the most common cause. Management typically involved cerclage fixation, leading to favorable outcomes postoperatively.

Key findings

  • The incidence of intraoperative calcar fractures was 0.74%, with individual study rates ranging from 0% to 10%.
  • Stem impaction was responsible for 72% of IOCFs during surgery.
  • Patient body mass index and use of smaller stems were associated with higher IOCF rates.
  • Postoperative complications were minimal, including low rates of femoral component loosening and revision surgery.

Why it matters

Understanding the incidence and management of intraoperative calcar fractures is crucial for orthopedic surgeons performing uncemented THAs. Awareness of risk factors can enhance surgical techniques and improve patient outcomes.

Source

PubMed · PMID 42777093

Published in JBJS Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Orthopedic Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.